NCT07053449Not yet recruiting
The Impact of Treatment for Chronic Hepatitis B Virus on Non-clinical Harms
The Impact of Treatment for Chronic Hepatitis B Virus on Non-clinical (Social) Harms Amongst Migrant Populations: A Qualitative Study. (B-SOCIAL)
Source: ClinicalTrials.gov · Last updated 16 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this qualitative study is to explore the impact of antiviral treatment, or none, for chronic hepatitis B virus on the non-clinical (social) harms experienced by migrant populations living in the UK. Two groups of participants living with hepatitis B virus will be interviewed, those taking the daily treatment, and those not prescribed any treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 15 Apr 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Nottingham University Hospitals NHS Trust
- Diseases
- Hepatitis B
- NCT number
- NCT07053449
What you commit to
- Study type: Observational
- Planned participants: 30
- From 1 Aug 2025 to the primary completion date, 31 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Emotionally distressed due to HBV diagnosis
Other
- Current episode of decompensated cirrhosis
- Current diagnosis of hepatocellular carcinoma
Who the study is looking for
- Chronic HBsAg
- Able to give informed consent in English
- Able to converse in English
- Any migrant population member (non-UK) including if born overseas or in the UK
- Aged 18 years and over
- Has never taken antiviral treatment for HBV (12-15 participants)
- Prescribed and taking any oral treatment for HBV for a minimum of 12 months (12-15 participants)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.